HKSTP
13.1.2023 13:25:39 CET | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) has partnered with world-leading innovation platform, Plug and Play, to call on ambitious startups and entrepreneurs around the world to join the seventh Elevator Pitch Competition 2023 (EPiC 2023), one of the biggest pitch events in Hong Kong. The final entry deadline for the Competition has also been extended to 20 January 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230113005179/en/
HKSTP CEO, Albert Wong, joins Plug and Play CEO, Saeed Amidi, to promote HKSTP’s EPiC 2023, calling all startups in the world to come to Hong Kong for a scale-up opportunity of a lifetime. (Photo: Business Wire)
This offers local and global startups the chance to join the combined HKSTP and Plug and Play eco-systems to launch their potential innovations onto the global stage. Interested parties on two technology tracks (FinTech and PropTech) only need to submit a 2-min video introduction to make a potentially life-changing decision. 50 shortlisted semi-finalists will have the golden opportunity to be considered by HKSTP Venture Fund for direct investment of up to US$5 million as well as market expansion support in Asia and beyond, plus the chance to win a cash prize of US$60,000 if crowned champion.
As the world’s leading accelerator, Plug and Play will leverage its global network to organise international competitions in Asia, Europe and Northern America throughout February to bring in overseas startups to the April final in Hong Kong.
Hong Kong provides the ideal platform to expand into the vast Asian market, being a gateway to both Mainland China and Asia. Startups joining EPiC 2023 can fully leverage the largest I&T ecosystem in Hong Kong and HKSTP’s direct connections to over 1,000 investors and more than 300 corporate partners.
Albert Wong, CEO of HKSTP, said: “This year, our flagship event EPiC is set to be the biggest and best-ever as we partner with world-renowned Plug and Play, elevating the investment platform to a truly global level. This collaboration cements HKSTP and Hong Kong as a unique global launchpad to rapidly scale up innovators on their growth journey, while achieving our mission to propel success and advance Hong Kong's I&T development.”
Saeed Amidi, CEO of Plug and Play, said: “Partnering with HKSTP on EPiC is a major step forward in our mission to harness the huge Asia opportunity to build the world’s leading innovation platform. We are partnering with changemakers like HKSTP to build a unique innovation ecosystem by connecting the brightest minds with world-leading corporations, VC firms, universities, and government agencies across multiple industries.’’
EPiC 2023 will take place at the iconic sky100 venue atop Hong Kong’s tallest building, International Commerce Centre, to create a genuine elevator pitch experience for startups.
Who can apply:
- Tech startups that are less than 10 years old
- Ideas should focus on one of the TWO technology tracks: FinTech and PropTech
Applications will close on 20 January 2023 at 23:59 (Hong Kong time).
Please visit the website (https://epic.hkstp.org/) for more information on EPiC 2023.
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 12,000 research professionals and over 1,200 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
About Plug and Play
Plug and Play was established in Sunnyvale, California - a region within the renowned Silicon Valley. Although officially founded in 2006, the early stages of the business could be traced back to 1998. The company contains business functions, including tech investment, corporate innovation, and innovation space. Plug and Play now has 50 regional offices in over 30 countries and regions worldwide. With nearly 20 years of experience in early-stage tech investment, Plug and Play has successfully invested in and incubated numerous big tech companies, including PayPal, Google, Dropbox, LendingClub, Guardant Health, Rappi, N26, Honey, etc. It has invested in over 1,500 startups and accelerated over 17,000 programs globally. Each year, Plug and Play provides open innovation services for over 500 world-leading corporations through over 1,000 matchmaking activities with cutting-edge technology companies.
Formally established in 2016, Plug and Play China currently has 3 regional innovation hubs in Beijing (China HQ), Shanghai (Plug and Play Innovation Hub - Yangtze River Delta Area), and Shenzhen (Shenzhen Innovation Center). Plug and Play China also provides open innovation services in Nanjing, Wuhan, Wuxi etc.
There are 4 main business functions across Plug and Play China’s innovation platform including corporate innovation, city innovation, tech investment, and innovation space.
It has built China's leading international innovation ecosystem and created a multi-dimensional open innovation platform that includes corporations, startups, universities and research labs, government agencies, venture capitalist firms, and city innovation partners.
Since 2016, Plug and Play China has engaged with 100+ industry-leading corporations, accelerated over 1700 startups, and has invested in over 150 startups including ApplyBoard, AutoX, Flexiv, ZiFiSense, ROBOTICPLUS.AI, INGEEK, Hexaflake, Authing, Yours, etc.
Please visit www.pnpchina.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005179/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
